"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 2 | 3 |
| 1997 | 3 | 1 | 4 |
| 1998 | 6 | 4 | 10 |
| 1999 | 8 | 2 | 10 |
| 2000 | 5 | 1 | 6 |
| 2001 | 9 | 3 | 12 |
| 2002 | 6 | 9 | 15 |
| 2003 | 12 | 17 | 29 |
| 2004 | 14 | 6 | 20 |
| 2005 | 24 | 15 | 39 |
| 2006 | 19 | 13 | 32 |
| 2007 | 19 | 13 | 32 |
| 2008 | 19 | 15 | 34 |
| 2009 | 22 | 23 | 45 |
| 2010 | 26 | 24 | 50 |
| 2011 | 17 | 29 | 46 |
| 2012 | 24 | 20 | 44 |
| 2013 | 31 | 27 | 58 |
| 2014 | 33 | 21 | 54 |
| 2015 | 43 | 23 | 66 |
| 2016 | 38 | 32 | 70 |
| 2017 | 42 | 24 | 66 |
| 2018 | 44 | 29 | 73 |
| 2019 | 40 | 43 | 83 |
| 2020 | 43 | 29 | 72 |
| 2021 | 43 | 33 | 76 |
| 2022 | 2 | 36 | 38 |
| 2023 | 2 | 13 | 15 |
| 2024 | 15 | 29 | 44 |
| 2025 | 28 | 24 | 52 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy. Cancer Res. 2025 Oct 01; 85(19):3737-3751.
-
Identifying and mitigating the biological effectors of the social determinants of health in cancer. J Natl Cancer Inst. 2025 Oct 01; 117(10):1981-1983.
-
Detection of Cancers Three Years prior to Diagnosis Using Plasma Cell-Free DNA. Cancer Discov. 2025 Sep 04; 15(9):1794-1802.
-
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis. Lancet Oncol. 2025 Sep; 26(9):1178-1190.
-
Characterization of the tumor immune microenvironment in pregnancy-associated breast cancer through multiplex immunohistochemistry and transcriptome analyses. Breast Cancer Res. 2025 Aug 26; 27(1):154.
-
Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors. ESMO Open. 2025 Aug; 10(8):105518.
-
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. Clin Cancer Res. 2025 Aug 01; 31(15):3249-3258.
-
Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures. Cancer Cell. 2025 Sep 08; 43(9):1731-1757.e17.
-
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. Cell Rep Med. 2025 Aug 19; 6(8):102255.
-
Unveiling spatial heterogeneity in medulloblastoma: A multi-omics analysis of cellular state and geographical organization. Neuro Oncol. 2025 Jul 30; 27(6):1611-1627.